AbbVie Transforming patients' lives

In Belgium, AbbVie mobilises its 170 employees to conduct more than 65 phase I to IV clinical trials in 56 research centres with 640 patients. This makes it the largest recruiter of patients for clinical trials. The top 10 pharmaceutical companies in Belgium work day in, day out on transforming patients’ lives. A bbVie is already focusing on the next therapeutic innovation. Its mission? Develop therapies and drugs to treat the most serious and complex diseases. The company pursues this mission in collaboration with universities, public authorities, health professionals and patient associations. AbbVie became a separate company from Abbott in 2013. Today, it combines the experience of a pharmaceutical leader with the dynamism of a biotech company, cutting-edge scientific research with expertise. It is driven by a passion for finding new solutions in four key therapeutic areas. Immunology is the central focus of AbbVie’s activities. For more than 20 years, the company has used its extensive scientific experience for the treatment of chronic autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease, etc. Its innovative treatments have already benefited over one million patients worldwide. Today, the company builds on these solid foundations to develop new-generation treatments designed to improve the living comfort of patients. AbbVie is also very active in the area of oncology. The company is convinced that the fight against cancer requires a paradigm shift and a transformation in the management of cancers. With this in mind, it is conducting more than 200 clinical trials in more than 20 types of cancer (haematological and solid tumours) by using its in-depth knowledge of key biological mechanisms re lated to the development of cancers. These tests have enabled AbbVie to develop a new molecule that, via an innovative action mechanism, for the first time allows to restore the capacity of cancer cells to die (apoptosis). Thibault Massart, General Manager BeLux © AbbVie

On the neuroscience front, AbbVie is already re cognised for its treatment targeting advanced stage Parkinson’s disease. Today, it investigates this further by exploring other methods to better meet these patients’ needs. However, researchers at AbbVie also deal with other neurodegenerative diseases such as multiple sclerosis and Alzheimer’s disease. The focus is on the prevention of degen eration of nerve cells, but also on their protection and regeneration.

Virology also remains high on AbbVie’s agenda. The company prides itself on having defeated the hepatitis C virus, a virus that causes chronic liver disease which, only a few years ago, was hardly curable. New treatments for hepatitis C can cure virtually all patients over a short treatment period (8 weeks for certain patients). This scientific advance makes the WHO’s objective to eradicate hepatitis C by 2030 more realistic.

Beyond its technological expertise, AbbVie is committed to sustainable healthcare. Against the background of an ageing population and the increase in chronic diseases, the company endeavours to help the authorities find concrete solutions to support the health system - an essential complement to providing the best possible pa tient care. For AbbVie, sustainable healthcare can only be achieved through the reorganisation of healthcare, patient empowerment, and early intervention. All these challenges need to be addressed as we chart a course for a new horizon full of possibilities, where health is accessible to all.

AbbVie sa/nv Avenue Einstein 14 - B-1300 Wavre Tel.: +32 10 47 78 11 Email: communications.be@abbvie.com - https://www.abbvie.be